LifeCell/Stryker Howmedica deal
This article was originally published in The Gray Sheet
Bone graft marketing services pact calls for Stryker Howmedica Osteonics to be the exclusive agent for LifeCell's demineralized bone matrix (DBM) product. LifeCell expects to launch the yet-to-be-named product by the end of 2003. Under the terms of the deal, announced June 5, LifeCell will be responsible for development and distribution of the product while Stryker will handle marketing, solicitation and customer education...
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.